Chemotherapy is currently the standard of care for ADC lung cancer patients in the absence of EGFR or other targetable molecular alterations (EML4-ALK), with erlotinib approved only for EGFR-mutated ADC patients in first-line treatment. This evidence concerns the gene EML4 and lung carcinoma.